https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53815 Wed 28 Feb 2024 16:05:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33645 Wed 24 Nov 2021 15:51:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30962 Wed 11 Apr 2018 10:28:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22760 Wed 11 Apr 2018 09:54:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16611 0.001). Trends in receptor binding site density measurements supported this observation (P = 0.07). Glucocorticoid exposure increased β₁-adrenoceptor mRNA levels in the right ventricle of preterm hearts (P = 0.008) but did not alter expression in the left ventricle (P>0.1). Relative abundance of a1A-adrenoceptor mRNA was the same in preterm and term piglet hearts (P = >0.1) but was reduced by maternal glucocorticoid treatment (P<0.01); a2A-adrenoceptor mRNA abundance was higher in untreated and glucocorticoid exposed preterm piglet hearts than in term piglets (P<0.001). There was no difference between male and female piglets in mRNA abundance of any of the genes studied. In conclusion, there is reduced mRNA abundance of β₁-adrenoceptors in the preterm pig heart. If this lower expression of β-adrenoceptors occurs in human preterm infants, it could explain their poor cardiovascular function and their frequent failure to respond to commonly used inotropes.]]> Wed 11 Apr 2018 09:23:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38417 Wed 08 Sep 2021 12:33:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7592 Sat 24 Mar 2018 08:37:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10796 50% compared with the initial measurement is associated with mortality.]]> Sat 24 Mar 2018 08:08:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17993 24 h of life. Data sources: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CINAHL, Cochrane Library, clinicaltrials.gov, controlled-trials.com, American Pediatric and European Paediatric Research Societies and Effective Care of the Newborn Infant. Review methods: ystematic review with network meta-analysis of randomised studies comparing intravenous indomethacin, ibuprofen or placebo for PDA in preterm infants at >24 h of life. Results: ten trials compared intravenous indomethacin versus intravenous ibuprofen, nine intravenous indomethacin versus placebo and one intravenous ibuprofen versus placebo. Both intravenous indomethacin (pooled RR 2.39 (95% CI 2.05 to 2.78)) and intravenous ibuprofen (RR 2.40 (95% CI 2.03 to 2.84)) closed a PDA more effectively than placebo. Intravenous ibuprofen was associated with approximately 30% greater risk of chronic lung disease than intravenous indomethacin (RR 1.28 (95% CI 1.03 to 1.60)) or placebo (RR 1.29 (95% CI 0.99 to 1.70)). Differences in risk or benefit were not significant between any combination of intravenous indomethacin, intravenous ibuprofen or placebo groups for intraventricular haemorrhage, necrotising enterocolitis and death. Reporting on neurological outcomes was insufficient for pooling. Conclusions: intravenous indomethacin or ibuprofen administered to preterm infants for PDA at >24 h of life promoted ductal closure, but other short-term benefits were not seen. Treatment with intravenous ibuprofen may increase the risk of chronic lung disease. Good-quality evidence of treatment effect on morbidity, mortality and improved neurodevelopment is urgently needed.]]> Sat 24 Mar 2018 07:56:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5184 Sat 24 Mar 2018 07:47:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27954 Sat 24 Mar 2018 07:38:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40786 Mon 18 Jul 2022 16:07:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43044 Mon 12 Sep 2022 12:38:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39651 Fri 17 Jun 2022 13:19:10 AEST ]]>